Evidence map›Paper›PMID 38769532›Full record

ArticleGenome medicine2024

Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes.

Xueqi Cao, Sandra Huber, Ata Jadid Ahari, Franziska R Traube, Marc Seifert, Christopher C Oakes, Polina Secheyko, Sergey Vilov, Ines F Scheller, Nils Wagner and 7 more

Abstract read
In one paragraph

Article in Genome medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Hematological Malignancies: Molecular Mechanisms and Therapy.International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xueqi CaoSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.ORCID 0009-0005-9019-0403
Sandra HuberMunich Leukemia Laboratory (MLL), Munich, Germany.
Ata Jadid AhariSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.
Franziska R TraubeSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.ORCID 0000-0002-5691-1941
Marc SeifertDepartment of Haematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
Christopher C OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Polina SecheykoSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.
Sergey VilovComputational Health Center, Helmholtz Center Munich, Neuherberg, Germany.ORCID 0000-0002-2609-1356
Ines F SchellerSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.ORCID 0000-0003-4533-7857
Nils WagnerSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.
Vicente A YépezSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.ORCID 0000-0001-7916-3643
Piers BlomberyPeter MacCallum Cancer Centre, Melbourne, Australia.
Torsten HaferlachMunich Leukemia Laboratory (MLL), Munich, Germany.
Matthias HeinigSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany.ORCID 0000-0002-5612-1720
Leonhard WachutkaSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany. wachutka@cit.tum.de.ORCID 0000-0002-5959-040X
Stephan HutterMunich Leukemia Laboratory (MLL), Munich, Germany. stephan.hutter@mll.com.
Julien GagneurSchool of Computation, Information and Technology, Technical University of Munich, Garching, Germany. gagneur@in.tum.de.ORCID 0000-0002-8924-8365

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Bundesministerium für Bildung und Forschung 031L0203ABundesministerium für Bildung und Forschung 031L0203BBundesministerium für Bildung und Forschung 031L0203CNCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

backgroundRare oncogenic driver events, particularly affecting the expression or splicing of driver genes, are suspected to substantially contribute to the large heterogeneity of hematologic malignancies. However, their identification remains challenging.

methodsTo address this issue, we generated the largest dataset to date of matched whole genome sequencing and total RNA sequencing of hematologic malignancies from 3760 patients spanning 24 disease entities. Taking advantage of our dataset size, we focused on discovering rare regulatory aberrations. Therefore, we called expression and splicing outliers using an extension of the workflow DROP (Detection of RNA Outliers Pipeline) and AbSplice, a variant effect predictor that identifies genetic variants causing aberrant splicing. We next trained a machine learning model integrating these results to prioritize new candidate disease-specific driver genes.

resultsWe found a median of seven expression outlier genes, two splicing outlier genes, and two rare splice-affecting variants per sample. Each category showed significant enrichment for already well-characterized driver genes, with odds ratios exceeding three among genes called in more than five samples. On held-out data, our integrative modeling significantly outperformed modeling based solely on genomic data and revealed promising novel candidate driver genes. Remarkably, we found a truncated form of the low density lipoprotein receptor LRP1B transcript to be aberrantly overexpressed in about half of hairy cell leukemia variant (HCL-V) samples and, to a lesser extent, in closely related B-cell neoplasms. This observation, which was confirmed in an independent cohort, suggests LRP1B as a novel marker for a HCL-V subclass and a yet unreported functional role of LRP1B within these rare entities.

conclusionsAltogether, our census of expression and splicing outliers for 24 hematologic malignancy entities and the companion computational workflow constitute unique resources to deepen our understanding of rare oncogenic events in hematologic cancers.

Indexed as

Hematologic NeoplasmsTranscriptomeGene Expression ProfilingGene Expression Regulation, NeoplasticHumansOncogenesReceptors, LDLRNA SplicingReceptors, LDLAberrant expressionAberrant splicingDriver gene predictionHairy cell leukemia variant (HCL-V)LRP1B

Identifiers

PMID38769532
PMCPMC11103968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.